Evidence map›Paper›PMID 39301864›Full record

ReviewAnnals of medicine2024

Progress in diagnosis and treatment of hypertension combined with left ventricular hypertrophy.

Yongjin Han, Yanqiu Li, Zhen Wu, Ying Pei, Saien Lu, Haijie Yu, Yingxian Sun, Xueyao Zhang

Abstract readReview
In one paragraph

Review in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yongjin HanDepartment of Cardiology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Yanqiu LiDepartment of Cardiology, Yixian People's Hospital, Jinzhou, Liaoning Province, China.
Zhen WuDepartment of Cardiology, Yixian People's Hospital, Jinzhou, Liaoning Province, China.
Ying PeiDepartment of Cardiology, Yixian People's Hospital, Jinzhou, Liaoning Province, China.
Saien LuDepartment of Cardiology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Haijie YuDepartment of Cardiology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.ORCID 0009-0005-5090-4475
Yingxian SunDepartment of Cardiology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.ORCID 0000-0002-1854-0385
Xueyao ZhangDepartment of Cardiology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.ORCID 0000-0003-4794-5514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension, a worldwide cardiovascular issue, is known to result in significant damage to the left ventricle. Left ventricular hypertrophy refers to an increase in ventricular mass, which is not only the primary independent risk factor for cardiovascular disease onset but also independently related to the risk of death.

objectivesWe sought to synthesize the existing literature on the occurrence and correlation between hypertension and left ventricular hypertrophy and the progress.

methodsA scoping review was performed based on the methodological framework developed by Arksey & O'Malley. Search in the Pubmed database with no language restrictions, as of September 1, 2024.

resultsOf the 8110 articles retrieved, 110 were finally included. The selected articles were published between 1987 and 2024, with 55.5% (61/110) of the studies in the last five years and 14.5% (16/110) of 2024. The studies covered diagnosis, epidemiology, pathophysiology, prognosis, and treatment of hypertension with left ventricular hypertrophy.

conclusionThe literature reviewed suggests that studies on hypertension combined with left ventricular hypertrophy covered a variety of clinical progress, especially the clinical trial results of some new drugs that may bring great hope for treatment.

Indexed as

Antihypertensive AgentsHypertensionHypertrophy, Left VentricularHumansPrognosisRisk FactorsAntihypertensive Agentsdiagnostic evaluationhypertensionLeft ventricular hypertrophy

Identifiers

PMID39301864
PMCPMC11418038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.